Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Treasury Shares (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Treasury Shares for 5 consecutive years, with $56250.0 as the latest value for Q3 2025.

  • Quarterly Treasury Shares fell 81.83% to $56250.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $56250.0 through Sep 2025, down 81.83% year-over-year, with the annual reading at $22200.0 for FY2024, 86.2% down from the prior year.
  • Treasury Shares hit $56250.0 in Q3 2025 for Krystal Biotech, roughly flat from $56250.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $330332.0 in Q1 2024 to a low of $22200.0 in Q4 2024.
  • Historically, Treasury Shares has averaged $113857.6 across 5 years, with a median of $70350.0 in 2022.
  • Biggest YoY gain for Treasury Shares was 643.99% in 2024; the steepest drop was 86.2% in 2024.
  • Year by year, Treasury Shares stood at $98800.0 in 2021, then plummeted by 32.59% to $66600.0 in 2022, then surged by 141.59% to $160900.0 in 2023, then plummeted by 86.2% to $22200.0 in 2024, then soared by 153.38% to $56250.0 in 2025.
  • Business Quant data shows Treasury Shares for KRYS at $56250.0 in Q3 2025, $56250.0 in Q2 2025, and $56250.0 in Q1 2025.